Investigational Drug Details
| Drug ID: | D414 |
| Drug Name: | Efruxifermin |
| Synonyms: | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Fibroblast growth factor receptor agonist |
| Therapeutic Category: | anti-fibrotic, improves metabolic status |
| Clinical Trial Progress: | Phase 2 completed (NCT03976401: Treatment with efruxifermin significantly reduced HFF in patients with F1-F3 stage NASH, with an acceptable safety profile.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0209 | NCT05039450 | Phase 2 | Recruiting | No Results Available | July 30, 2021 | February 17, 2022 | Details |
| L0216 | NCT04767529 | Phase 2 | Active, not recruiting | No Results Available | February 16, 2021 | February 14, 2022 | Details |
| L0224 | NCT03976401 | Phase 2 | Completed | No Results Available | May 28, 2019 | February 28, 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A02792 | 34239138 | Nat Med | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. | Details |
| A28960 | 34773249 | Br J Pharmacol | Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. | Details |
| A50136 | 35507280 | Curr Atheroscler Rep | Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. | Details |